ANABV - AnaptysBio, Inc. Common Stock When Issued

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates.

Sector

Healthcare

Industry

Biotechnology

Market Cap

$1.26B

Beta

0.41

52-Week Range

41.99-49.76

CEO

Daniel R. Faga

IPO Date

Apr 6, 2026

Exchange

NASDAQ

ANABV Options Snapshot

Options pricing data for ANABV is refreshed daily after the close. When listed contracts exist, this page surfaces the latest at-the-money implied volatility, max pain strike, dealer gamma exposure (GEX), and 25-delta skew. Listed contracts and live snapshots appear once the options chain has been published by the exchange for the most recent session.

What This Page Covers

The ANABV overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.